AR066649A1 - Reovirus mutantes y metodos de elaboracion y uso de los mismos - Google Patents

Reovirus mutantes y metodos de elaboracion y uso de los mismos

Info

Publication number
AR066649A1
AR066649A1 ARP080102139A ARP080102139A AR066649A1 AR 066649 A1 AR066649 A1 AR 066649A1 AR P080102139 A ARP080102139 A AR P080102139A AR P080102139 A ARP080102139 A AR P080102139A AR 066649 A1 AR066649 A1 AR 066649A1
Authority
AR
Argentina
Prior art keywords
reovirus
methods
elaboration
mutants
same
Prior art date
Application number
ARP080102139A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR066649A1 publication Critical patent/AR066649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un reovirus mutante, CARACTERIZADO PORQUE dicho reovirus mutante comprende una primera mutacion, en donde dicha primera mutacion reduce la expresion de un polipéptido sigma3, elimina esencialmente la expresion de un polipéptido sigma3 o da como resultado la ausencia de un polipéptido sigma3 funcional. Reivindicacion 9: Una partícula subviral infecciosa (ISVP) de reovirus, CARACTERIZADA PORQUE fue manipulada genéticamente. También se proveen composiciones que incluyen reovirus mutantes y métodos de uso de dichos reovirus mutantes.
ARP080102139A 2007-05-21 2008-05-20 Reovirus mutantes y metodos de elaboracion y uso de los mismos AR066649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93925507P 2007-05-21 2007-05-21

Publications (1)

Publication Number Publication Date
AR066649A1 true AR066649A1 (es) 2009-09-02

Family

ID=40031362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102139A AR066649A1 (es) 2007-05-21 2008-05-20 Reovirus mutantes y metodos de elaboracion y uso de los mismos

Country Status (15)

Country Link
US (1) US20080292594A1 (es)
EP (1) EP2150613B1 (es)
JP (1) JP2010527593A (es)
CN (2) CN104195115A (es)
AR (1) AR066649A1 (es)
AU (1) AU2008253505B2 (es)
CA (1) CA2680661C (es)
DK (1) DK2150613T3 (es)
ES (1) ES2611455T3 (es)
HK (1) HK1136006A1 (es)
IL (1) IL200690A (es)
MX (1) MX2009012420A (es)
TW (1) TW200909581A (es)
WO (1) WO2008141448A1 (es)
ZA (1) ZA200907017B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
CN101820892A (zh) * 2007-10-22 2010-09-01 昂科利蒂克斯生物科技公司 增殖性疾病的治疗方案
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
MX2010012857A (es) * 2008-05-27 2010-12-20 Oncolytics Biotech Inc Supresion de produccion de citoquina proinflamatoria durante la terapia de reovirus oncolitico.
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2015070323A1 (en) 2013-11-15 2015-05-21 Oncolytics Biotech Inc. Oncolytic viruses and increased cancer treatment regimens
EP3417866B1 (en) 2016-02-16 2020-12-23 Osaka University Medicinal composition for treating fibrosis
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
EP1098961B1 (en) * 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
EP2189162B1 (en) * 2000-11-09 2013-11-27 Oncolytics Biotech Inc. Methods for the treatment of cellular proliferative disorders
WO2002074940A1 (en) * 2001-03-16 2002-09-26 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders

Also Published As

Publication number Publication date
JP2010527593A (ja) 2010-08-19
EP2150613B1 (en) 2016-10-19
IL200690A0 (en) 2011-08-01
CA2680661A1 (en) 2008-11-27
IL200690A (en) 2014-02-27
CA2680661C (en) 2018-05-29
TW200909581A (en) 2009-03-01
CN104195115A (zh) 2014-12-10
WO2008141448A1 (en) 2008-11-27
DK2150613T3 (en) 2017-01-30
HK1136006A1 (zh) 2010-06-18
ES2611455T3 (es) 2017-05-09
ZA200907017B (en) 2010-12-29
AU2008253505A1 (en) 2008-11-27
CN101679953A (zh) 2010-03-24
MX2009012420A (es) 2009-12-09
EP2150613A1 (en) 2010-02-10
AU2008253505B2 (en) 2014-09-04
EP2150613A4 (en) 2011-01-19
US20080292594A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
AR066649A1 (es) Reovirus mutantes y metodos de elaboracion y uso de los mismos
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
AR064725A1 (es) Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso
DE60143517D1 (de) Wiederherstellung der gelenken mit mesenchymalen stammzellen
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
HN2005029978A (es) Formulaciones
AU2008326599A8 (en) Modulation of the immune response
WO2002009650A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
TW200712688A (en) Light diffusing films, methods of making the same, and articles using the same
PL1635863T3 (pl) Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
CR10372A (es) Anticuerpos anti-tat226 e inmunoconjugados
AR054937A1 (es) Goma de mascar biodegradable
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
TW200703884A (en) Miller-compensated amplifier
RS52914B (en) AMORPHIC SOLID DISPERSION OF 7-CHLOR-N, N, 5-TRIMETHYL-4-OXO-3-PHENYL-3,5, -Dihydro-4H-pyridazino (4,5-B) INDOL-1-ACETAMIDE
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
MX2008011844A (es) Formulaciones de sitaxsentano de sodio.
WO2005086938A3 (en) Artificial mutation controls for diagnostic testing
WO2008120201A3 (en) An isolated population of cells and methods of generating and using same
AR110487A1 (es) Composición de limpieza de prótesis dentales, toallita de limpieza y uso
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
DE602005027687D1 (de) Kanone für geladene teilchen
GB2379446A (en) Cells,culture methods and their uses

Legal Events

Date Code Title Description
FB Suspension of granting procedure